Cargando…

A Novel COVID-19 Severity Score is Associated With Survival in Patients Undergoing Percutaneous Dilational Tracheostomy

INTRODUCTION: Tracheostomy in patients with COVID-19 is a controversial and difficult clinical decision. We hypothesized that a recently validated COVID-19 Severity Score (CSS) would be associated with survival in patients considered for tracheostomy. METHODS: We reviewed 77 mechanically ventilated...

Descripción completa

Detalles Bibliográficos
Autores principales: Hambrecht, Amanda, Krowsoski, Leandra, DiMaggio, Charles, Hong, Charles, Medina, Benjamin, Thomas McDevitt, John, McRae, Michael, Mukherjee, Vikramjit, Uppal, Amit, Bukur, Marko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676158/
https://www.ncbi.nlm.nih.gov/pubmed/36914992
http://dx.doi.org/10.1016/j.jss.2022.10.098
_version_ 1784833526871359488
author Hambrecht, Amanda
Krowsoski, Leandra
DiMaggio, Charles
Hong, Charles
Medina, Benjamin
Thomas McDevitt, John
McRae, Michael
Mukherjee, Vikramjit
Uppal, Amit
Bukur, Marko
author_facet Hambrecht, Amanda
Krowsoski, Leandra
DiMaggio, Charles
Hong, Charles
Medina, Benjamin
Thomas McDevitt, John
McRae, Michael
Mukherjee, Vikramjit
Uppal, Amit
Bukur, Marko
author_sort Hambrecht, Amanda
collection PubMed
description INTRODUCTION: Tracheostomy in patients with COVID-19 is a controversial and difficult clinical decision. We hypothesized that a recently validated COVID-19 Severity Score (CSS) would be associated with survival in patients considered for tracheostomy. METHODS: We reviewed 77 mechanically ventilated COVID-19 patients evaluated for decision for percutaneous dilational tracheostomy (PDT) from March to June 2020 at a public tertiary care center. Decision for PDT was based on clinical judgment of the screening surgeons. The CSS was retrospectively calculated using mean biomarker values from admission to time of PDT consult. Our primary outcome was survival to discharge, and all patient charts were reviewed through August 31, 2021. ROC curve and Youden index were used to estimate an optimal cut-point for survival. RESULTS: The mean CSS for 42 survivors significantly differed from that of 35 nonsurvivors (CSS 52 versus 66, P = 0.003). The Youden index returned an optimal CSS of 55 (95% confidence interval 43-72), which was associated with a sensitivity of 0.8 and a specificity of 0.6. The median CSS was 40 (interquartile range 27, 49) in the lower CSS (<55) group and 72 (interquartile range 66, 93) in the high CSS (≥55 group). Eighty-seven percent of lower CSS patients underwent PDT, with 74% survival, whereas 61% of high CSS patients underwent PDT, with only 41% surviving. Patients with high CSS had 77% lower odds of survival (odds ratio = 0.2, 95% confidence interval 0.1-0.7). CONCLUSIONS: Higher CSS was associated with decreased survival in patients evaluated for PDT, with a score ≥55 predictive of mortality. The novel CSS may be a useful adjunct in determining which COVID-19 patients will benefit from tracheostomy. Further prospective validation of this tool is warranted.
format Online
Article
Text
id pubmed-9676158
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-96761582022-11-21 A Novel COVID-19 Severity Score is Associated With Survival in Patients Undergoing Percutaneous Dilational Tracheostomy Hambrecht, Amanda Krowsoski, Leandra DiMaggio, Charles Hong, Charles Medina, Benjamin Thomas McDevitt, John McRae, Michael Mukherjee, Vikramjit Uppal, Amit Bukur, Marko J Surg Res Acute Care Surgery INTRODUCTION: Tracheostomy in patients with COVID-19 is a controversial and difficult clinical decision. We hypothesized that a recently validated COVID-19 Severity Score (CSS) would be associated with survival in patients considered for tracheostomy. METHODS: We reviewed 77 mechanically ventilated COVID-19 patients evaluated for decision for percutaneous dilational tracheostomy (PDT) from March to June 2020 at a public tertiary care center. Decision for PDT was based on clinical judgment of the screening surgeons. The CSS was retrospectively calculated using mean biomarker values from admission to time of PDT consult. Our primary outcome was survival to discharge, and all patient charts were reviewed through August 31, 2021. ROC curve and Youden index were used to estimate an optimal cut-point for survival. RESULTS: The mean CSS for 42 survivors significantly differed from that of 35 nonsurvivors (CSS 52 versus 66, P = 0.003). The Youden index returned an optimal CSS of 55 (95% confidence interval 43-72), which was associated with a sensitivity of 0.8 and a specificity of 0.6. The median CSS was 40 (interquartile range 27, 49) in the lower CSS (<55) group and 72 (interquartile range 66, 93) in the high CSS (≥55 group). Eighty-seven percent of lower CSS patients underwent PDT, with 74% survival, whereas 61% of high CSS patients underwent PDT, with only 41% surviving. Patients with high CSS had 77% lower odds of survival (odds ratio = 0.2, 95% confidence interval 0.1-0.7). CONCLUSIONS: Higher CSS was associated with decreased survival in patients evaluated for PDT, with a score ≥55 predictive of mortality. The novel CSS may be a useful adjunct in determining which COVID-19 patients will benefit from tracheostomy. Further prospective validation of this tool is warranted. Elsevier Inc. 2023-03 2022-11-21 /pmc/articles/PMC9676158/ /pubmed/36914992 http://dx.doi.org/10.1016/j.jss.2022.10.098 Text en © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Acute Care Surgery
Hambrecht, Amanda
Krowsoski, Leandra
DiMaggio, Charles
Hong, Charles
Medina, Benjamin
Thomas McDevitt, John
McRae, Michael
Mukherjee, Vikramjit
Uppal, Amit
Bukur, Marko
A Novel COVID-19 Severity Score is Associated With Survival in Patients Undergoing Percutaneous Dilational Tracheostomy
title A Novel COVID-19 Severity Score is Associated With Survival in Patients Undergoing Percutaneous Dilational Tracheostomy
title_full A Novel COVID-19 Severity Score is Associated With Survival in Patients Undergoing Percutaneous Dilational Tracheostomy
title_fullStr A Novel COVID-19 Severity Score is Associated With Survival in Patients Undergoing Percutaneous Dilational Tracheostomy
title_full_unstemmed A Novel COVID-19 Severity Score is Associated With Survival in Patients Undergoing Percutaneous Dilational Tracheostomy
title_short A Novel COVID-19 Severity Score is Associated With Survival in Patients Undergoing Percutaneous Dilational Tracheostomy
title_sort novel covid-19 severity score is associated with survival in patients undergoing percutaneous dilational tracheostomy
topic Acute Care Surgery
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676158/
https://www.ncbi.nlm.nih.gov/pubmed/36914992
http://dx.doi.org/10.1016/j.jss.2022.10.098
work_keys_str_mv AT hambrechtamanda anovelcovid19severityscoreisassociatedwithsurvivalinpatientsundergoingpercutaneousdilationaltracheostomy
AT krowsoskileandra anovelcovid19severityscoreisassociatedwithsurvivalinpatientsundergoingpercutaneousdilationaltracheostomy
AT dimaggiocharles anovelcovid19severityscoreisassociatedwithsurvivalinpatientsundergoingpercutaneousdilationaltracheostomy
AT hongcharles anovelcovid19severityscoreisassociatedwithsurvivalinpatientsundergoingpercutaneousdilationaltracheostomy
AT medinabenjamin anovelcovid19severityscoreisassociatedwithsurvivalinpatientsundergoingpercutaneousdilationaltracheostomy
AT thomasmcdevittjohn anovelcovid19severityscoreisassociatedwithsurvivalinpatientsundergoingpercutaneousdilationaltracheostomy
AT mcraemichael anovelcovid19severityscoreisassociatedwithsurvivalinpatientsundergoingpercutaneousdilationaltracheostomy
AT mukherjeevikramjit anovelcovid19severityscoreisassociatedwithsurvivalinpatientsundergoingpercutaneousdilationaltracheostomy
AT uppalamit anovelcovid19severityscoreisassociatedwithsurvivalinpatientsundergoingpercutaneousdilationaltracheostomy
AT bukurmarko anovelcovid19severityscoreisassociatedwithsurvivalinpatientsundergoingpercutaneousdilationaltracheostomy
AT hambrechtamanda novelcovid19severityscoreisassociatedwithsurvivalinpatientsundergoingpercutaneousdilationaltracheostomy
AT krowsoskileandra novelcovid19severityscoreisassociatedwithsurvivalinpatientsundergoingpercutaneousdilationaltracheostomy
AT dimaggiocharles novelcovid19severityscoreisassociatedwithsurvivalinpatientsundergoingpercutaneousdilationaltracheostomy
AT hongcharles novelcovid19severityscoreisassociatedwithsurvivalinpatientsundergoingpercutaneousdilationaltracheostomy
AT medinabenjamin novelcovid19severityscoreisassociatedwithsurvivalinpatientsundergoingpercutaneousdilationaltracheostomy
AT thomasmcdevittjohn novelcovid19severityscoreisassociatedwithsurvivalinpatientsundergoingpercutaneousdilationaltracheostomy
AT mcraemichael novelcovid19severityscoreisassociatedwithsurvivalinpatientsundergoingpercutaneousdilationaltracheostomy
AT mukherjeevikramjit novelcovid19severityscoreisassociatedwithsurvivalinpatientsundergoingpercutaneousdilationaltracheostomy
AT uppalamit novelcovid19severityscoreisassociatedwithsurvivalinpatientsundergoingpercutaneousdilationaltracheostomy
AT bukurmarko novelcovid19severityscoreisassociatedwithsurvivalinpatientsundergoingpercutaneousdilationaltracheostomy